Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab in food allergy extension study
NCT05678959Phase 3Terminated
- Sponsor
- Novartis
- Start
- Apr 2023
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of ligelizumab in food allergy, sponsored by Novartis. Started Apr 2023; status: terminated.
02
Drugs
ligelizumab
03
Conditions
food allergy
Beyond the preview
Go deeper on NCT05678959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05678959.